Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
February 28, 2026

Nereus / tradipitant for vomiting induced by motion sickness in adults as of February 2026

MARA Rating Company February 28, 2026

Ziftomenib for nPM1-mutant R/R AML as of February 2026

MARA Rating Company February 28, 2026

Nuzolvence / zoliflodacin for uncomplicated Urogenital Gonorrhea in US, EU5, and Japan as of February 2026

MARA Rating Company February 28, 2026

Hernexeos / zongertinib for previously Treated HER2-Mutant NSCLC as of February 2026

MARA Rating Company February 28, 2026

Linvoseltamab-gcpt for relapsed or refractory multiple myeloma after at least four prior lines of therapy as of February 2026

MARA Rating Company February 28, 2026

Yartemlea / narsoplimab-wuug for treatment of transplant-associated thrombotic microangiopathy as of February 2026

MARA Rating Company February 28, 2026

Nerandomilast for idiopathic Pulmonary Fibrosis as of February 2026

MARA Rating Company February 28, 2026

Paltusotine for treating adult acromegaly in the US, EU five, and Japan as of February 2026

MARA Rating Company February 28, 2026

Penpulimab-kcqx for recurrent or Metastatic Nasopharyngeal Carcinoma as of February 2026

MARA Rating Company February 28, 2026

Redemplo / plozasiran for familial Chylomicronemia Syndrome as of February 2026

MARA Rating Company February 28, 2026